Financial Statements

PDS Biotechnology Corporation (PDSB)

$3.96

+0.11 (+2.86%)

Cash Flow Statement

All numbers are in thousands
Year XLSX
2022
XLSX
2021
XLSX
2020
XLSX
2019
XLSX
2018
Operating Cash Flow -25,709.71-12,486.07-13,149.14-18,073.47-33,153.29
Net Income -40,854.86-16,918.48-14,847.38-6,998.61-40,868.01
Depreciation & Amortization 0.095.3615.6198.41174.35
Deferred income taxes ----381.512,822.58
Stock-based compensation 5,196.164,110.20452.293,176.137,614.61
Change in working capital 4,474.9875.821,069.66-4,604.55-3,428.50
Other non-cash items 5,473.92241.03160.68-9,363.35531.67
Investing Cash Flow ---29,381.51-
Acquisitions ---29,106.51-
Other Investing Activites ---275-
Financing Cash Flow 34,287.2448,889.1229,826.96750-20,268.81
Debt repayment -449.33----20,990
Dividends payments -0.27----
Common Stock Repurchased -0.27----
Common Stock Issuance 9,856.1248,54529,756.50750-
Other Financing Activites 24,881344.1370.46-721.20
Accounts payables -90.12-105.82217.50-1,977.67-3,969.69
Other working capital 4,565.10181.64852.16-2,626.88541.19
Cash at beginning of period 65,242.6228,839.5612,161.74103.6988,067.65
Cash at end of period 73,820.1665,242.6228,839.5612,161.7434,645.55
Net cash flow / Change in cash 8,577.5436,403.0616,677.8312,058.04-53,422.10
Free Cash Flow -25,709.71-12,486.07-13,149.14-18,073.47-33,153.29

PDS Biotechnology Corporation income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes PDS Biotechnology Corporation FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.